中国现代神经疾病杂志 ›› 2025, Vol. 25 ›› Issue (6): 496-502. doi: 10.3969/j.issn.1672-6731.2025.06.007

• 脑静脉系统疾病 • 上一篇    下一篇

2 重症脑静脉窦血栓形成血管内治疗预后分析

聂放1, 蔡恒2, 唐伟2, 李进伟1, 付开磊1, 李志清1,*()   

  1. 1. 110001 中国医科大学附属第一医院卒中中心 辽宁省神经疾病大数据重点实验室 辽宁省沈阳市神经系统疑难重症临床医学研究中心
    2. 110004 沈阳, 中国医科大学附属盛京医院神经外科
  • 收稿日期:2025-04-10 出版日期:2025-06-25 发布日期:2025-07-04
  • 通讯作者: 李志清
  • 作者简介:

    聂放与蔡恒对本文有同等贡献

    NIE Fang and CAI Heng contributed equally to the article

  • 基金资助:
    四大慢病重大专项(2023ZD0505600); 四大慢病重大专项(2023ZD0505603); 辽宁省自然科学基金计划指导计划项目(2019-ZD-0757); 辽宁省沈阳市科技计划项目(21-172-9-17)

Prognostic analysis of endovascular treatment for severe cerebral venous sinus thrombosis

Fang NIE1, Heng CAI2, Wei TANG2, Jin-wei LI1, Kai-lei FU1, Zhi-qing LI1,*()   

  1. 1. Stroke Center; Key Laboratory of Neurological Disease Big Data of Liaoning Province; Shenyang Clinical Medical Research Center for Difficult and Serious Diseases of the Nervous System, The First Hospital of China Medical University, Shenyang 110001, Liaoning, China
    2. Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China
  • Received:2025-04-10 Online:2025-06-25 Published:2025-07-04
  • Contact: Zhi-qing LI
  • Supported by:
    Noncommunicable Chronic Diseases-National Science and Technology Major Project(2023ZD0505600); Noncommunicable Chronic Diseases-National Science and Technology Major Project(2023ZD0505603); Natural Science Foundation of Liaoning(2019-ZD-0757); Shenyang Science and Technology Bureau in Liaoning(21-172-9-17)

摘要:

目的: 探讨重症脑静脉窦血栓形成血管内治疗效果和预后,为疾病治疗提供新思路。方法: 回顾分析2017年10月至2024年12月中国医科大学附属第一医院和中国医科大学附属盛京医院诊断与治疗的31例重症脑静脉窦血栓形成患者的临床经过,通过术后即刻DSA评估静脉窦再通情况,选择围手术期并发症发生率、随访期间病死率和末次随访时改良Rankin量表(mRS)评分等多项标准评价患者预后。结果: 采用多种血管内治疗技术联合应用方式,术后即刻达到静脉窦完全再通者7例(22.58%)、部分再通24例(77.42%)。围手术期并发症发生率为6.45%(2/31),无新发脑梗死。平均随访(6.60 ± 3.40)个月,随访期间无死亡病例,末次随访时预后良好(mRS评分≤ 2分)者28例(90.32%)。结论: 血管内治疗可以有效降低重症脑静脉窦血栓形成患者病死率并改善预后,但治疗需基于个体化评估,严格掌握适应证。

关键词: 窦血栓形成,颅内, 危重病, 血栓切除术, 血栓溶解疗法, 抗凝药, 预后

Abstract:

Objective: To explore the efficacy and prognosis of endovascular treatment for severe cerebral venous sinus thrombosis (CVST), providing new insights for the treatment of CVST. Methods: The clinical course of 31 severe CVST patients admitted to The First Hospital of China Medical University and Shengjing Hospital of China Medical University from October 2017 to December 2024 was analyzed retrospectively. The condition of venous sinus recanalization was assessed through immediately postoperative DSA examination, and the prognosis was evaluated based on criteria such as perioperative complication rate, mortality rate during follow‐up, and modified Rankin Scale (mRS) score at the last follow‐ up. Results: A combination of multiple endovascular treatment techniques was used. Immediately after the operation, 7 patients (22.58%) achieved complete recanalization of the venous sinus and 24 patients (77.42%) achieved partial recanalization. The incidence of perioperative complication rate was 6.45% (2/31), and there was no new cerebral infarction. The average follow ‐ up period was (6.60 ± 3.40) months. No deaths were reported during the follow ‐ up period. At the last follow ‐ up, 28 patients (90.32%) had a good prognosis (mRS score ≤ 2). Conclusions: Endovascular treatment can effectively reduce the mortality rate and improve the prognosis of patients with severe CVST, but individualized assessment is required, and indications must be strictly controlled.

Key words: Sinus thrombosis, intracranial, Critical illness, Thrombectomy, Thrombolytic therapy, Anticoagulants, Prognosis